

I'm not a robot!



1. Management of hepatitis B and HIV coinfection. Available from: . Grossblatt N. Hepatitis and Liver Cancer: National Strategy for Prevention and Control of Hepatitis B and C. Institute of Medicine (US) Committee on the Prevention and Control of Viral Hepatitis Infections. Washington, DC: National Academies Press; 2010. [Google Scholar]3. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. *J Infect Dis.* 2010;202:192-201. doi:10.1086/653622. [PubMed] [Google Scholar]4. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. *Hepatology.* 2012;56:422-433. doi:10.1002/hep.24804. [PubMed] [Google Scholar]5. Terrault NA, Bzowej NH, Chang KM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. *Hepatology.* 2016;63:261-283. doi:10.1002/hep.28156. [PMC free article] [PubMed] [Google Scholar]6. Tran TT. Hepatitis B in Pregnancy. *Clin Infect Dis.* 2016;62(Suppl 4):S314-S317. doi:10.1093/cid/ciw092. [PMC free article] [PubMed] [Google Scholar]7. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. *J Viral Hepat.* 2006;13:787-798. doi:10.1111/j.1365-2893.2006.00787.x. [PubMed] [Google Scholar]8. Smith EA, Jacques-Carroll L, Walker TY, Sirotkin B, Murphy TV. The national perinatal hepatitis B prevention program, 1994-2008. *Pediatrics.* 2012;129:609-616. doi:10.1542/peds.2011-2866. [PubMed] [Google Scholar]9. Singh AE, Plitt SS, Osiowy C, Surynicz K, Kouadio E, Preiksaitis J, et al. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. *J Viral Hepat.* 2011;18:468-473. doi:10.1111/j.1365-2893.2010.01333.x. [PubMed] [Google Scholar]10. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. *J Infect Dis.* 1994;170:1418-1423. doi:10.1093/infdis/170.6.1418. [PubMed] [Google Scholar]11. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol.* 2012;57:167-185. doi:10.1016/j.jhep.2012.02.010. [PubMed] [Google Scholar]12. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. *J Hepatol.* 2003;39:S64-S69. doi:10.1016/S0168-8278(03)00141-7. [PubMed] [Google Scholar]13. Publicover J, Gaggar A, Nishimura S, Van Horn CM, Goodsell A, Muench MO, et al. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. *J Clin Invest.* 2013;123:3728-3739. doi:10.1172/JCI68182. [PMC free article] [PubMed] [Google Scholar]14. Carey I, D'Antiga L, Bansal S, Longhi MS, Ma Y, Mesa IR, et al. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy. *J Virol.* 2011;85:2416-2428. doi:10.1128/JVI.01449-10. [PMC free article] [PubMed] [Google Scholar]15. Lin HH, Lee TY, Chen DS, Sung JL, Ohto H, Etoh T, et al. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. *J Pediatr.* 1987;111:877-881. [PubMed] [Google Scholar]16. Lazizi Y, Badur S, Perk Y, Ilter O, Pillot J. Selective unresponsiveness to HBsAg vaccine in newborns related with an in utero passage of hepatitis B virus DNA. *Vaccine.* 1997;15:1095-1100. [PubMed] [Google Scholar]17. Kim GA, Lee HC, Kim MJ, Ha Y, Park EJ, An J, et al. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. *J Hepatol.* 2015;62:1092-1099. doi:10.1016/j.jhep.2014.11.031. [PubMed] [Google Scholar]18. Cohen E, Tran TT. Hepatitis B in the female population. *Gastroenterol Clin North Am.* 2016;45:359-370. doi:10.1016/j.gtc.2016.02.011. [PubMed] [Google Scholar]19. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. *Hepatology.* 2009;49:S185-S195. doi:10.1002/hep.22885. [PubMed] [Google Scholar]20. Chu CM, Lin CC, Chen YC, Jeng WJ, Lin SM, Liaw YF. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. *Br J Cancer.* 2012;107:2010-2015. doi:10.1038/bjc.2012.474. [PMC free article] [PubMed] [Google Scholar]21. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. *Gastroenterology.* 2010;139:483-490. doi:10.1053/j.gastro.2010.04.052. [PubMed] [Google Scholar]22. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. *N Engl J Med.* 2005;352:2682-2695. doi:10.1056/NEJMoa043470. [PubMed] [Google Scholar]23. Shaheen AA, Myers RP. The outcomes of pregnancy in patients with cirrhosis: a population-based study. *Liver Int.* 2010;30:275-283. doi:10.1111/j.1478-3231.2009.02153.x. [PubMed] [Google Scholar]24. Kim HY, Choi JY, Park CH, Jang JW, Kim CW, Bae SH, et al. Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus. *J Clin Virol.* 2013;56:299-305. doi:10.1016/j.jcv.2012.11.019. [PubMed] [Google Scholar]25. Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. *Clin Gastroenterol Hepatol.* 2012;10:452-459. doi:10.1016/j.cgh.2011.10.041. [PubMed] [Google Scholar]26. Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. *J Hepatol.* 2005;43:771-775. doi:10.1016/j.jhep.2005.05.023. [PubMed] [Google Scholar]27. Lao TT, Chan BC, Leung WC, Ho LF, Tse KY. Maternal hepatitis B infection and gestational diabetes mellitus. *J Hepatol.* 2007;47:46-50. doi:10.1016/j.jhep.2007.02.014. [PubMed] [Google Scholar]28. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. *Obstet Gynecol.* 2007;110:941-956. doi:10.1097/01.AOG.0000263930.28382.2a. [PubMed] [Google Scholar]29. Nguyen G, Garcia RT, Nguyen N, Trinh H, Keeffe EB, Nguyen MH. Clinical course of hepatitis B virus infection during pregnancy. *Aliment Pharmacol Ther.* 2009;29:755-764. doi:10.1111/j.1365-2036.2009.03932.x. [PubMed] [Google Scholar]30. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. *J Viral Hepat.* 2012;19:e18-e25. doi:10.1111/j.1365-2893.2011.01492.x. [PubMed] [Google Scholar]31. Bai H, Zhang L, Ma L, Dou XG, Feng GH, Zhao GZ. Relationship of hepatitis B virus infection of placental barrier and hepatitis B virus intra-uterine transmission mechanism. *World J Gastroenterol.* 2007;13:3625-3630. [PMC free article] [PubMed] [Google Scholar]32. Kar P, Mishra S. Management of hepatitis B during pregnancy. *Expert Opin Pharmacother.* 2016;17:301-310. doi:10.1517/14656566.2016.1118051. [PubMed] [Google Scholar]33. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. *J Hepatol.* 2011;55:1215-1221. doi:10.1016/j.jhep.2011.02.032. [PubMed] [Google Scholar]34. Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. *Clin Gastroenterol Hepatol.* 2012;10:520-526. doi:10.1016/j.cgh.2012.01.019. [PubMed] [Google Scholar]35. Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. *Hepatology.* 2015;62:375-386. doi:10.1002/hep.27837. [PubMed] [Google Scholar]36. Han GR, Jiang HX, Zhao W, Ge CY, Xu CL, Pan C. Lamivudine use in the 2nd or 3rd trimester of pregnancy has similar efficacy in preventing vertical transmission (VT) of chronic hepatitis B (CHB) in highly viremic mothers. *Hepatology.* 2011;54:479A. [Google Scholar]37. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. *J Viral Hepat.* 2009;16:94-103. doi:10.1111/j.1365-2893.2008.01056.x. [PubMed] [Google Scholar]38. Ayres A, Yuen L, Jackson KM, Manoharan S, Glass A, Maley M, et al. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. *J Viral Hepat.* 2014;21:809-817. doi:10.1111/jvh.12212. [PubMed] [Google Scholar]39. Whittaker G, Herrera JL. Hepatitis B in Pregnancy. *South Med J.* 2014;107:195-200. doi:10.1097/SMJ.0000000000000077. [PubMed] [Google Scholar]40. Lamberth JR, Reddy SC, Pan JJ, Dasher KJ. Chronic hepatitis B infection in pregnancy. *World J Hepatol.* 2015;7:1233-1237. doi:10.4254/wjh.v7.i9.1233. [PMC free article] [PubMed] [Google Scholar]41. Lee SD, Lo KJ, Tsai YT, Wu JC, Wu TC, Yang ZL, et al. Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus. *Lancet.* 1988;2:833-834. doi:10.1016/S0140-6736(88)92792-4. [PubMed] [Google Scholar]42. Hu Y, Chen J, Wen J, Xu C, Zhang S, Xu B, et al. Effect of elective cesarean section on the risk of mother-to-child transmission of hepatitis B virus. *BMC Pregnancy Childbirth.* 2013;13:119. doi:10.1186/1471-2393-13-119. [PMC free article] [PubMed] [Google Scholar]43. Society for Maternal-Fetal Medicine (SMFM) Dionne-Odom J, Tita AT, Silverman NS. Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. *Am J Obstet Gynecol.* 2016;214:6-14. doi:10.1016/j.ajog.2015.09.100. [PubMed] [Google Scholar]44. Protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR Recomm Rep. 1990;39:1-26. [PubMed] [Google Scholar]45. Benaboud S, Pruvost A, Coffie PA, Ekouévi DK, Urien S, Arrivé E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Côte d'Ivoire, in the ANRS 12109 TEMAA Study, Step 2. *Antimicrob Agents Chemother.* 2011;55:1315-1317. doi:10.1128/AAC.00514-10. [PMC free article] [PubMed] [Google Scholar]